🇺🇸 Selective serotonin reuptake inhibitors in United States

60 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 60

Most-reported reactions

1. Drug Interaction — 10 reports (16.67%)
2. Toxicity To Various Agents — 9 reports (15%)
3. Anxiety — 8 reports (13.33%)
4. Drug Ineffective — 6 reports (10%)
5. Convulsion — 5 reports (8.33%)
6. Drug Abuse — 5 reports (8.33%)
7. Serotonin Syndrome — 5 reports (8.33%)
8. Depression — 4 reports (6.67%)
9. Loss Of Consciousness — 4 reports (6.67%)
10. Malaise — 4 reports (6.67%)

Source database →

Frequently asked questions

Is Selective serotonin reuptake inhibitors approved in United States?

Selective serotonin reuptake inhibitors does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Selective serotonin reuptake inhibitors in United States?

Faculdade de Medicina do ABC is the originator. The local marketing authorisation holder may differ — check the official source linked above.